法里西马布与阿弗利塞普治疗多性胆道血管病变的一年期结果:一项比较研究
Jaejin Cho1, Hee Yong Han1, Sangmin Park1
1Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
Eye (London, England)
|September 9, 2025
概括
内法利西马布和阿弗利塞普特在多性胆道血管病变 (PCV) 中显示了可比的视觉和解剖改善. 在12个月的时间里,法里西马布证明了色素上皮质脱落 (PED) 厚度的优异降低.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 血管生物学 血管生物学
背景情况:
- 多性冠状血管病变 (PCV) 是一种与年龄相关的黄斑变性的一种亚型.
- 内疗法是PCV的标准治疗方法.
- 将法利西马布等新药与阿弗利塞普特等已知治疗方法进行比较,对于优化患者的治疗结果至关重要.
研究的目的:
- 为了比较内法利西马布与阿弗利塞普特在PCV治疗先前的患者中的疗效.
- 在12个月的治疗期间评估视觉敏度和解剖学变化.
主要方法:
- 对111名以前没有接受过治疗的PCV患者进行了回顾性分析.
- 患者接受了内法利西马布 (30只眼睛) 或阿弗利塞普特 (81只眼睛).
- 三个月一次的加重注射,然后进行12个月的结果评估.
主要成果:
- 费里西马布和阿弗利塞普都显著改善了最佳校正视敏度 (BCVA) 和减少了视网膜中心厚度,没有显著差异.
- 与aflibercept相比,Faricimab显示出最大色素上皮质脱落 (PED) 厚度的显著减少.
- 在法里西马布组中,实现>50%PED厚度减小的眼睛比例更高.
结论:
- 内法利西马布和阿弗利塞普在12个月内为PCV患者提供了可比的视觉和解剖效益.
- 法里西马布在减少PED厚度方面表现出卓越的疗效,这是PCV的一个关键解剖学标志物.
- 这些发现支持法里西马布作为PCV的有效治疗选择,特别是用于管理PED.
相关概念视频
01:27Open Angle Glaucoma: Treatment
963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
01:28Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466